Skip to Content

9 3 5215 (Hydrochlorothiazide and Moexipril Hydrochloride 25 mg / 15 mg)

Pill with imprint 9 3 5215 is Yellow, Capsule-shape and has been identified as Hydrochlorothiazide and Moexipril Hydrochloride 25 mg / 15 mg. It is supplied by Teva Pharmaceuticals USA.

Hydrochlorothiazide/moexipril is used in the treatment of high blood pressure and belongs to the drug class ACE inhibitors with thiazides. There is positive evidence of human fetal risk during pregnancy. Hydrochlorothiazide/moexipril 25 mg / 15 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for 9 3 5215

Hydrochlorothiazide and moexipril hydrochloride 25 mg / 15 mg 9 3 5215 Front
Hydrochlorothiazide and moexipril hydrochloride 25 mg / 15 mg 9 3 5215 Back
Hydrochlorothiazide and moexipril hydrochloride 25 mg / 15 mg 9 3 5215
Hydrochlorothiazide and moexipril hydrochloride 25 mg / 15 mg 9 3 5215
Hydrochlorothiazide and moexipril hydrochloride 25 mg / 15 mg 9 3 5215

Hydrochlorothiazide and Moexipril Hydrochloride

Imprint:
9 3 5215
Strength:
25 mg / 15 mg
Color:
Yellow
Size:
13.00 mm
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
ACE inhibitors with thiazides
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Teva Pharmaceuticals USA
Inactive Ingredients:

Note: Inactive ingredients may vary.

Labelers / Repackagers:

NDC CodeLabeler / Repackager
00093-5215 Teva Pharmaceuticals USA, Inc.
42291-0578 AvKare, Inc.
54868-3443 Physicians Total Care Inc. (repackager)

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide